|
| Press Releases |
|
 |
|
| Thursday, August 4, 2022 |
|
|
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022 |
| Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype. more info >> |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA. more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. more info >> |
|
|
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 |
| Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401). more info >> |
|
| Wednesday, July 6, 2022 |
|
|
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab. more info >> |
|
| Tuesday, June 28, 2022 |
|
|
E.Design Insurance and Eisai Enter Into Business Alliance |
| E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." more info >> |
|
| Friday, June 24, 2022 |
|
|
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO). more info >> |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
HG Semiconductor Places 30 Million New Shares and Announces Subscription of 60 Million Shares and 60 Million Warrants by Founder of GCL Technology Mr. Zhu Gongshan
Aug 8, 2022 08:30 HKT/SGT
|
|
|
Lab-Grown Diamond Facility in Singapore to Commence Commercial Production
Aug 8, 2022 07:00 HKT/SGT
|
|
|
The 37th Edition of World AI Show Addressed the Necessity of Boosting AI Adoption in Malaysia 
Aug 5, 2022 17:30 HKT/SGT
|
|
|
MHI to Issue its First Transition Bond
Aug 5, 2022 17:17 JST
|
|
|
Mitsubishi Heavy Industries Achieves 22% YoY Increase in Order Intake and 52% YoY Increase in Net Profit in a Challenging First Quarter
Aug 5, 2022 16:40 JST
|
|
|
Modern Companies Cannot Afford to Ignore the Digital Transformation
Aug 5, 2022 15:33 HKT/SGT
|
|
|
Honda Signs Agreement to Transfer Shares of Honda Lock Mfg. to MinebeaMitsumi
Aug 5, 2022 15:24 JST
|
|
|
'Gumball Dreams' to have its International Premiere at the 79th Venice International Film Festival
Aug 5, 2022 10:08 HKT/SGT
|
|
|
World's Biggest Deal for Humanoid Robots Inked
Aug 4, 2022 22:42 HKT/SGT
|
|
|
Asian Licensing Conference explores latest trends and forges new business opportunities
Aug 4, 2022 18:00 HKT/SGT
|
|
|
MHI Group Signs Sponsorship Agreement with Thailand's Muangthong United Football Club
Aug 4, 2022 16:44 JST
|
|
|
Meet the 5G Ecosystem at BYOND MOBILE
Aug 4, 2022 15:23 HKT/SGT
|
|
|
Showa Denko Announces 2022 2Q Consolidated Financial Results
Aug 4, 2022 14:00 HKT/SGT
|
|
|
Hitachi Energy Supports Huge Step in Germany's Energy Transition
Aug 4, 2022 10:02 JST
|
|
|
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
Aug 4, 2022 9:25 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
